A trio of biotech firms IPOed on Friday – and saw double-digit gains on their trading debuts. Among the newly listed biotech offerings was PMV Pharma, which today’s article explains “is a precision-oncology company that is developing small-molecule therapies targeting p53 mutations. P53 is a tumor-suppressor protein, known as the ‘guardian of the genome,’ that has the ability to eliminate cancer cells.” For more on these newly listed biotech stocks and their early performance, CLICK HERE.
Early Performance Of 3 Newly Listed Biotech Stocks
- by Alex Clarke
Tags:Biotech OfferingsEarly Performing BiotechsInvestingNewly Listed Biotech Stocksp53 MutationsPharma StocksPMVStocks